Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12607000040460
Ethics application status
Approved
Date submitted
16/08/2006
Date registered
12/01/2007
Date last updated
14/11/2011
Type of registration
Retrospectively registered

Titles & IDs
Public title
A randomised clinical trial (RCT) of the effect of Neuro-Emotional Technique (NET) on the clinical manifestations of primary overt hypothyroidism
Scientific title
A randomised clinical trial (RCT) of the effect of Neuro-Emotional Technique (NET) on the clinical manifestations of primary overt hypothyroidism
Secondary ID [1] 252148 0
nil
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypothyroidism 1534 0
Condition category
Condition code
Metabolic and Endocrine 1631 1631 0 0
Other metabolic and endocrine disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Neuro-Emotional Technique (NET) Neuro-Emotional Technique is a technique used by chiropractors which is similar to Cognitive behavioural therapy (CBT). Participants in the treatment group will receive 10 NET treatments over a period of 6 weeks. The treatments will last for approximately 5-20 mins in duration.
Intervention code [1] 1315 0
Treatment: Other
Comparator / control treatment
Participants in the placebo (sham) intervention group will receive a non-therapeutic sham intervention. This placebo intervention mimics the NET protocol with the purported therapeutic components removed and replaced with innocous steps. The placebo intervention will be administered at the same frequency as the treatment group.
Control group
Placebo

Outcomes
Primary outcome [1] 258734 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Depression scores as measured by the Depression, Anxiety, Stress (DASS) questionnaire.
Timepoint [1] 258734 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [1] 3927 0
Basal Temperature (BT) measurement
Timepoint [1] 3927 0
Measures will be performed every day for the duration of the trial (6 months).
Secondary outcome [2] 3928 0
Basal Heart Rate (BHR) measurement
Timepoint [2] 3928 0
Measures will be performed every day for the duration of the trial (6 months).
Secondary outcome [3] 263471 0
Self report daily health and well being questionniare.
Timepoint [3] 263471 0
Measures will be performed every day for the duration of the trial (6 months).
Secondary outcome [4] 264780 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include measurement of Anxiety and Stress using the DASS questionnaire.
Timepoint [4] 264780 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [5] 264781 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Serum thyroid stimulating hormone (TSH)
Timepoint [5] 264781 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [6] 264782 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Serum thyroxine (T4)
Timepoint [6] 264782 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [7] 264783 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Serum Triiodothyronine (T3)
Timepoint [7] 264783 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [8] 264784 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Serum Thyroid peroxidase antibodies (anti-TPO)
Timepoint [8] 264784 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [9] 264785 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Serum Thyroglobulin antibodies (anti-TG)
Timepoint [9] 264785 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.
Secondary outcome [10] 264786 0
To evaluate the influence of Neuro-Emotional Technique (NET) on the clinical manifestations of individuals with primary overt hypothyroidism. Outcome measures include: Short Form -36 (SF-36) questionnaire
Timepoint [10] 264786 0
Administered at the beginning of the trial, and at 6 weeks and 6 months.

Eligibility
Key inclusion criteria
Hypothyroid sufferers.
Minimum age
18 Years
Maximum age
Not stated
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Iatrogenic hypothyroidism, < 18 years, significant co-morbidities, Deaf/mute, Non-English speaking, Serious illness/mental illness, Pregnant, Individuals recently diagnosed (within the last 6 months) with hypothyroidism, medications that are known to influence thyroid function other than standard meds for hypothyroidism.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Person responsible for applying inclusion/exclusion criteria was not aware of the group to which the participant would be allocated. Participants are not advised which group they have been allocated. Central randomisation performed by phone /computer well after participants have been accepted into the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Using random.org This is a web site which assists the randomisation of participants by providing a true random sequence generator
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Doube blind. Participants are blind as to the group they have been allocated (treatment or sham). In addition, the assessors (pathologists) are blind to the allocation. The data analyst is also blinded to the status of the participants.
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
10/12/2006
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
102
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 1777 0
Charities/Societies/Foundations
Name [1] 1777 0
Australian Spinal Research Foundation
Country [1] 1777 0
Australia
Primary sponsor type
Individual
Name
A/Prof Rod Bonello
Address
Department of Chiropractic, Macquarie University, NSW 2109
Country
Australia
Secondary sponsor category [1] 1582 0
None
Name [1] 1582 0
None
Address [1] 1582 0
Country [1] 1582 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 3333 0
Macquarie University Human Ethics Committee-Macquarie University Sydney
Ethics committee address [1] 3333 0
Ethics committee country [1] 3333 0
Australia
Date submitted for ethics approval [1] 3333 0
Approval date [1] 3333 0
Ethics approval number [1] 3333 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 27922 0
Address 27922 0
Country 27922 0
Phone 27922 0
Fax 27922 0
Email 27922 0
Contact person for public queries
Name 10504 0
Benjamin Brown
Address 10504 0
Department of Chiropractic, Macquarie University, 2109
Country 10504 0
Australia
Phone 10504 0
+61 02 9850 7694
Fax 10504 0
+61 02 9850 6565
Email 10504 0
[email protected]
Contact person for scientific queries
Name 1432 0
Benjamin Brown
Address 1432 0
Department of Chiropractic, Macquarie University, 2109
Country 1432 0
Australia
Phone 1432 0
+61 02 9850 7694
Fax 1432 0
+61 02 9850 6565
Email 1432 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseThe influence of a biopsychosocial-based treatment approach to primary overt hypothyroidism: A protocol for a pilot study.2010https://dx.doi.org/10.1186/1745-6215-11-106
N.B. These documents automatically identified may not have been verified by the study sponsor.